Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19

Detalhes bibliográficos
Autor(a) principal: Geovane Marques Ferreira
Data de Publicação: 2023
Tipo de documento: Dissertação
Idioma: por
Título da fonte: Repositório Institucional da UFMG
Texto Completo: http://hdl.handle.net/1843/55418
Resumo: COVID-19 is a deadly disease caused by the SARS-CoV-2 pandemic, which has remained a public health threat for over three years. In contrast to the severity of COVID-19, so far, there are few drugs capable of efficiently preventing or delaying the development of severe COVID-19. More importantly, studies focusing on compounds controlled intranasally to act more quickly in the airways and mucous membranes of individuals with severe COVID-19 under mechanical ventilation are still reduced. In this sense, BromAc® is a combination of bromelain and acetylcysteine (NAC), currently used for the treatment of pseudomyxoma (Phase 3) and has been studied for repositioning in the treatment of COVID-19. Therefore, in the present study, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® ex-vivo in a sample of tracheal aspirates from critically ill patients with COVID-19 under mechanical ventilation and the anti-inflammatory effect of BromAc® in an in vitro system using peripheral blood cells stimulated with inactivated SARS-CoV-2. Our results sadden that BromAc® exhibited a robust mucolytic effect in the exception of tracheal aspirates from patients with COVID-19 in a dose-dependent manner. In addition, BromAc® has demonstrated anti-inflammatory activity, reducing the cytokine storm in the tracheal aspirate samples from patients with COVID-19 and in culture supernatants. The combination showed reduced chemokines compared to NAC individually. The action of the combined compounds on regulatory cytokines such as IL-10 was also observed. Furthermore, BromAc® was able to modulate CD16+ and CD14+ cells after in vitro treatment of blood cells with BromAc®. These results indicate a robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill patients, indicating its potential as a therapeutic strategy for COVID-19. Clinical trials are needed to define the safety and efficacy of BromAc® in the treatment of the disease, which has been the greatest challenge of the 21st century.
id UFMG_77bbca5dff15f1672835f13923d7e5e9
oai_identifier_str oai:repositorio.ufmg.br:1843/55418
network_acronym_str UFMG
network_name_str Repositório Institucional da UFMG
repository_id_str
spelling Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19Evaluation of the mucolytic and anti-inflammatory activity of BromAc® applied to the treatment of COVID-19MicrobiologiaCOVID-19BromelaínasAcetilcisteínaMicrobiologiaCovid-19BromelaínasAcetilcisteínaCOVID-19 is a deadly disease caused by the SARS-CoV-2 pandemic, which has remained a public health threat for over three years. In contrast to the severity of COVID-19, so far, there are few drugs capable of efficiently preventing or delaying the development of severe COVID-19. More importantly, studies focusing on compounds controlled intranasally to act more quickly in the airways and mucous membranes of individuals with severe COVID-19 under mechanical ventilation are still reduced. In this sense, BromAc® is a combination of bromelain and acetylcysteine (NAC), currently used for the treatment of pseudomyxoma (Phase 3) and has been studied for repositioning in the treatment of COVID-19. Therefore, in the present study, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® ex-vivo in a sample of tracheal aspirates from critically ill patients with COVID-19 under mechanical ventilation and the anti-inflammatory effect of BromAc® in an in vitro system using peripheral blood cells stimulated with inactivated SARS-CoV-2. Our results sadden that BromAc® exhibited a robust mucolytic effect in the exception of tracheal aspirates from patients with COVID-19 in a dose-dependent manner. In addition, BromAc® has demonstrated anti-inflammatory activity, reducing the cytokine storm in the tracheal aspirate samples from patients with COVID-19 and in culture supernatants. The combination showed reduced chemokines compared to NAC individually. The action of the combined compounds on regulatory cytokines such as IL-10 was also observed. Furthermore, BromAc® was able to modulate CD16+ and CD14+ cells after in vitro treatment of blood cells with BromAc®. These results indicate a robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill patients, indicating its potential as a therapeutic strategy for COVID-19. Clinical trials are needed to define the safety and efficacy of BromAc® in the treatment of the disease, which has been the greatest challenge of the 21st century.A COVID-19 é uma doença letal causada pela pandemia SARS-CoV-2, que permanece uma ameaça à saúde pública há mais de três anos. Em contraste com a gravidade do COVID-19, até o momento, existem poucos medicamentos capazes de prevenir ou retardar o desenvolvimento do COVID-19 grave de forma eficiente. Mais importante, ainda são escassos os estudos com foco em compostos administradas por via intranasal para agir mais rapidamente nas vias aéreas e muco de indivíduos com COVID-19 grave sob ventilação mecânica. Nesse sentido, BromAc® é uma combinação de bromelina e acetilcisteína (NAC), atualmente utilizada para o tratamento de pseudomixoma (Fase 3) e tem sido estudada para o reposicionamento no tratamento de COVID-19. Portanto, no presente estudo, procurou-se examinar o efeito mucolítico e anti-inflamatório do BromAc® ex-vivo em amostras de aspirado traqueal de pacientes críticos com COVID-19 sob ventilação mecânica e o efeito anti-inflamatório de BromAc® em um sistema in vitro utilizando células do sangue periférico estimuladas com o SARS-CoV-2 inativado. Nossos resultados demonstraram que o BromAc® exibiu um efeito mucolítico robusto em amostras de aspirado traqueal de pacientes com COVID-19 de maneira dose-dependente. Além disso, o BromAc® demonstrou atividade anti-inflamatória, reduzindo a ação da tempestade de citocinas em amostras de aspirado traqueal de pacientes com COVID-19 e nos sobrenadantes de cultura. A combinação apresentou redução de quimiocinas, em comparação com NAC isoladamente. Foi também observado a ação dos compostos combinados sobre citocinas reguladoras como IL-10. Além disso, o BromAc® foi capaz de modular as populações celulares CD16+ e CD14+ após o tratamento in vitro de células sanguíneas com BromAc®. Esses resultados indicam um efeito mucolítico e anti-inflamatório robusto do BromAc® em aspirados traqueais de pacientes críticos, indicando seu potencial como estratégia terapêutica para o COVID-19. Ensaios clínicos são necessários para definir a segurança e a eficácia do BromAc® no tratamento da doença, que tem sido o maior desafio do século XXI.CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível SuperiorUniversidade Federal de Minas GeraisBrasilICB - DEPARTAMENTO DE MICROBIOLOGIAPrograma de Pós-Graduação em MicrobiologiaUFMGJordana Grazziela Alves Coelho dos Reishttp://lattes.cnpq.br/0775593522993297Geovane Marques Ferreira2023-06-27T16:55:01Z2023-06-27T16:55:01Z2023-04-17info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/masterThesisapplication/pdfhttp://hdl.handle.net/1843/55418porinfo:eu-repo/semantics/openAccessreponame:Repositório Institucional da UFMGinstname:Universidade Federal de Minas Gerais (UFMG)instacron:UFMG2023-06-27T16:55:01Zoai:repositorio.ufmg.br:1843/55418Repositório InstitucionalPUBhttps://repositorio.ufmg.br/oairepositorio@ufmg.bropendoar:2023-06-27T16:55:01Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)false
dc.title.none.fl_str_mv Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
Evaluation of the mucolytic and anti-inflammatory activity of BromAc® applied to the treatment of COVID-19
title Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
spellingShingle Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
Geovane Marques Ferreira
Microbiologia
COVID-19
Bromelaínas
Acetilcisteína
Microbiologia
Covid-19
Bromelaínas
Acetilcisteína
title_short Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
title_full Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
title_fullStr Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
title_full_unstemmed Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
title_sort Avaliação da atividade mucolítica e antiinflamatória do BromAc® aplicado ao tratamento da COVID-19
author Geovane Marques Ferreira
author_facet Geovane Marques Ferreira
author_role author
dc.contributor.none.fl_str_mv Jordana Grazziela Alves Coelho dos Reis
http://lattes.cnpq.br/0775593522993297
dc.contributor.author.fl_str_mv Geovane Marques Ferreira
dc.subject.por.fl_str_mv Microbiologia
COVID-19
Bromelaínas
Acetilcisteína
Microbiologia
Covid-19
Bromelaínas
Acetilcisteína
topic Microbiologia
COVID-19
Bromelaínas
Acetilcisteína
Microbiologia
Covid-19
Bromelaínas
Acetilcisteína
description COVID-19 is a deadly disease caused by the SARS-CoV-2 pandemic, which has remained a public health threat for over three years. In contrast to the severity of COVID-19, so far, there are few drugs capable of efficiently preventing or delaying the development of severe COVID-19. More importantly, studies focusing on compounds controlled intranasally to act more quickly in the airways and mucous membranes of individuals with severe COVID-19 under mechanical ventilation are still reduced. In this sense, BromAc® is a combination of bromelain and acetylcysteine (NAC), currently used for the treatment of pseudomyxoma (Phase 3) and has been studied for repositioning in the treatment of COVID-19. Therefore, in the present study, we sought to examine the mucolytic and anti-inflammatory effect of BromAc® ex-vivo in a sample of tracheal aspirates from critically ill patients with COVID-19 under mechanical ventilation and the anti-inflammatory effect of BromAc® in an in vitro system using peripheral blood cells stimulated with inactivated SARS-CoV-2. Our results sadden that BromAc® exhibited a robust mucolytic effect in the exception of tracheal aspirates from patients with COVID-19 in a dose-dependent manner. In addition, BromAc® has demonstrated anti-inflammatory activity, reducing the cytokine storm in the tracheal aspirate samples from patients with COVID-19 and in culture supernatants. The combination showed reduced chemokines compared to NAC individually. The action of the combined compounds on regulatory cytokines such as IL-10 was also observed. Furthermore, BromAc® was able to modulate CD16+ and CD14+ cells after in vitro treatment of blood cells with BromAc®. These results indicate a robust mucolytic and anti-inflammatory effect of BromAc® in tracheal aspirates from critically ill patients, indicating its potential as a therapeutic strategy for COVID-19. Clinical trials are needed to define the safety and efficacy of BromAc® in the treatment of the disease, which has been the greatest challenge of the 21st century.
publishDate 2023
dc.date.none.fl_str_mv 2023-06-27T16:55:01Z
2023-06-27T16:55:01Z
2023-04-17
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/masterThesis
format masterThesis
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://hdl.handle.net/1843/55418
url http://hdl.handle.net/1843/55418
dc.language.iso.fl_str_mv por
language por
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Universidade Federal de Minas Gerais
Brasil
ICB - DEPARTAMENTO DE MICROBIOLOGIA
Programa de Pós-Graduação em Microbiologia
UFMG
publisher.none.fl_str_mv Universidade Federal de Minas Gerais
Brasil
ICB - DEPARTAMENTO DE MICROBIOLOGIA
Programa de Pós-Graduação em Microbiologia
UFMG
dc.source.none.fl_str_mv reponame:Repositório Institucional da UFMG
instname:Universidade Federal de Minas Gerais (UFMG)
instacron:UFMG
instname_str Universidade Federal de Minas Gerais (UFMG)
instacron_str UFMG
institution UFMG
reponame_str Repositório Institucional da UFMG
collection Repositório Institucional da UFMG
repository.name.fl_str_mv Repositório Institucional da UFMG - Universidade Federal de Minas Gerais (UFMG)
repository.mail.fl_str_mv repositorio@ufmg.br
_version_ 1823248244846624768